Effect of Early Versus Late Administration of Human Recombinant Erythropoietin on Transfusion Requirements in Premature Infants: Results of a Randomized, Placebo-Controlled, Multicenter Trial

The administration of recombinant human erythropoietin (rHuEPO), started after the first 2 weeks of life, reduces the transfusion requirement in premature infants. However, its use throughout the first 2 weeks of life, when anemia results predominantly from phlebotomy losses, remains controversial....

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 2000-05, Vol.105 (5), p.1066-1072
Main Authors: Donato, Hugo, Vain, Nestor, Rendo, Pablo, Vivas, Norma, Prudent, Luis, Larguia, Miguel, Digregorio, Jorge, Vecchiarelli, Carmen, Valverde, Regina, Garcia, Cecilia, Subotovsky, Patricia, Solana, Claudio, Gorenstein, Adriana, Private Hospitals Neonatal Network
Format: Article
Language:English
Subjects:
Anemia
Anemia in children
Anemia, Neonatal - blood
Anemia, Neonatal - prevention & control
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Babies
Biological and medical sciences
Blood Transfusion - statistics & numerical data
Care and treatment
Emergency and intensive care: neonates and children. Prematurity. Sudden death
Erythropoietin - administration & dosage
Erythropoietin, Recombinant
Health aspects
Humans
Infant, Newborn
Infant, Premature, Diseases - blood
Infant, Premature, Diseases - prevention & control
Intensive care medicine
Iron - therapeutic use
Medical sciences
Pediatric anemia
Pediatrics
Premature birth
Recombinant erythropoietin
Recombinant Proteins
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The administration of recombinant human erythropoietin (rHuEPO), started after the first 2 weeks of life, reduces the transfusion requirement in premature infants. However, its use throughout the first 2 weeks of life, when anemia results predominantly from phlebotomy losses, remains controversial. We investigated whether early use of rHuEPO would reduce the total transfusion requirement and/or the number of transfusions throughout the first 2 weeks of life. We randomized 114 infants with birth weight (BW)
ISSN:0031-4005
1098-4275
DOI:10.1542/peds.105.5.1066